Indivior Reports Strong Q4 & FY25 Results, Reaffirms Robust 2026 Guidance, and Authorizes $400M Share Buyback

summarizeSummary

Indivior Pharmaceuticals reported strong Q4 and full-year 2025 financial results, reaffirmed robust 2026 guidance, and announced a new $400 million share repurchase program.

check_boxKey Events

• Strong Q4 & FY25 Financial Performance

  Reported Q4 2025 total net revenue of $358 million (up 20% YoY) and full-year 2025 total net revenue of $1.239 billion (up 4% YoY). SUBLOCADE net revenue grew 30% in Q4 and 13% for the full year. Adjusted EBITDA increased 91% in Q4 to $142 million and 20% for the full year to $428 million.

• Reaffirmed Robust 2026 Guidance

  Reaffirmed full-year 2026 financial guidance, projecting Adjusted EBITDA of $535 million to $575 million, representing significant growth from 2025. This guidance was previously announced on January 8, 2026.

• New $400 Million Share Repurchase Program

  Authorized a new share repurchase program of up to $400 million with a term of up to 18 months, demonstrating a significant commitment to shareholder returns.

• Strategic Progress

  Completed Phase I of the Indivior Action Agenda and entered Phase II, focusing on accelerating U.S. SUBLOCADE dispense unit growth to the mid-teens and immediately accelerating adjusted EBITDA and cash flow.

auto_awesomeAnalysis

This 8-K filing details Indivior's strong financial performance for Q4 and full-year 2025, driven by significant growth in SUBLOCADE net revenue and Adjusted EBITDA. The company also reaffirmed its positive 2026 financial guidance, projecting substantial growth in Adjusted EBITDA. Crucially, Indivior authorized a new $400 million share repurchase program, representing a significant commitment to returning capital to shareholders and signaling strong confidence in future cash flow generation. This comprehensive update paints a very positive picture for investors, highlighting operational momentum and strategic capital deployment.